Persistence of Antibody to Influenza A/H5N1 Vaccine Virus: Impact of AS03 Adjuvant

The adjuvant AS03 is stockpiled for future formulations with new and existing vaccines for the control of pandemic influenza virus. We previously reported the immunogenicity of an A/H5N1 vaccine extemporaneously mixed with the AS03 adjuvant for 42 days following vaccination. This report extends thos...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical and vaccine immunology 2016-01, Vol.23 (1), p.73-77
Hauptverfasser:	Chen, Wilbur H, Jackson, Lisa A, Edwards, Kathryn M, Keitel, Wendy A, Hill, Heather, Noah, Diana L, Creech, C Buddy, Patel, Shital M, Mangal, Brian, Kotloff, Karen L
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvants, Immunologic Adolescent Adult alpha-Tocopherol - administration & dosage alpha-Tocopherol - immunology Antibodies, Viral - blood Antibodies, Viral - immunology Double-Blind Method Drug Combinations Female Humans Influenza A Virus, H5N1 Subtype - immunology Influenza Vaccines - administration & dosage Influenza Vaccines - immunology Influenza virus Influenza, Human - immunology Influenza, Human - prevention & control Male Middle Aged Polysorbates - administration & dosage Squalene - administration & dosage Squalene - immunology Time Factors Vaccination - adverse effects Vaccines Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The adjuvant AS03 is stockpiled for future formulations with new and existing vaccines for the control of pandemic influenza virus. We previously reported the immunogenicity of an A/H5N1 vaccine extemporaneously mixed with the AS03 adjuvant for 42 days following vaccination. This report extends those findings to 1 year after vaccination.
ISSN:	1556-6811 1556-679X
DOI:	10.1128/CVI.00475-15